Showing results (341-350 of 378) with videos related to
Sort By:
Pageof 38
Molecular Cancer Research : MCR|March 23, 2021
Comprehensive Molecular Profiling of Desmoplastic Small Round Cell TumorEmily K Slotkin, Anita S Bowman, Max F Levine, et al.Nature|September 28, 2010
Selective inhibition of BET bromodomainsPanagis Filippakopoulos, Jun Qi, Sarah Picaud, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2025
Improving global access to genomic profiling in rare pediatric cancersSameer Farouk Sait, Tara J O'Donohue, Tejus Bale, et al.Leukemia|July 24, 2015
Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG miceJ Etchin, J Montero, A Berezovskaya, et al.Blood Advances|November 17, 2021
Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantationMadhavi Lakkaraja, Michael Scordo, Audrey Mauguen, et al.Cell|September 6, 2011
BET bromodomain inhibition as a therapeutic strategy to target c-MycJake E Delmore, Ghayas C Issa, Madeleine E Lemieux, et al.Cancer Discovery|March 17, 2019
Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel <i>AKT1</i> Fusion-Driven CancerEmily K Slotkin, Daniel Diolaiti, Neerav N Shukla, et al.Blood Advances|June 28, 2023
Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantationRoni Tamari, Michael Scordo, Binni M Kunvarjee, et al.BMC Pediatrics|July 24, 2019
Study of Environmental Enteropathy and Malnutrition (SEEM) in Pakistan: protocols for biopsy based biomarker discovery and validationNajeeha T Iqbal, Sana Syed, Kamran Sadiq, et al.Blood|October 26, 2019
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALLKevin J Curran, Steven P Margossian, Nancy A Kernan, et al.Pageof 38